Article Details
Retrieved on: 2025-03-03 12:32:41
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The article, titled “The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here